Estados financieros detallados de Immix Biopharma, Inc. (IMMX): cuenta de resultados, balance general y flujo de caja. Sigue la evolución de márgenes, deuda, liquidez y rentabilidad año a año con hasta 20 años de histórico.
Resumen del Análisis
Márgenes de los últimos 12 meses: margen bruto 0.0%, margen operativo 0.0%, margen neto 0.0%.
Al precio actual de $11.92, IMMX presenta beneficios negativos (P/E no significativo) y un ROE del -38.44%. La capitalización bursátil es de $648M.
Cuenta de Resultados (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Ingresos | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Coste de Ventas | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Bruto | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| I+D | $583162 | $248149 | $126527 | $4.2M | $8.7M | $11.3M | $16.3M |
| Generales y Administrativos | $259337 | $205703 | $1.2M | $4.0M | $7.4M | $11.4M | $13.7M |
| Gastos Operativos | $842499 | $453852 | $1.4M | $8.2M | $16.1M | $22.7M | $30.0M |
| Beneficio Operativo | -$842499 | -$453852 | -$1.4M | -$8.2M | -$16.1M | -$22.7M | -$30.0M |
| EBITDA | -$841417 | -$451531 | -$24.2M | -$8.2M | -$15.6M | -$21.5M | -$29.6M |
| Gastos por Intereses | $109984 | $101976 | $179853 | $497 | 0 | 0 | 0 |
| Beneficio Antes de Impuestos | -$952259 | -$1.1M | -$24.4M | -$8.2M | -$15.6M | -$21.7M | -$29.4M |
| Impuestos | $20552 | $17547 | $6013 | $10268 | $26415 | $41037 | $37724 |
| Beneficio Neto | -$972811 | -$1.1M | -$24.4M | -$8.2M | -$15.4M | -$21.6M | -$29.4M |
| BPA | $-0.29 | $-0.15 | $-6.64 | $-0.59 | $-0.89 | $-0.76 | $-0.89 |
| BPA Diluido | $-0.29 | $-0.15 | $-6.64 | $-0.59 | $-0.89 | $-0.76 | $-0.89 |
| Acciones en Circulación (Diluidas) | $3.4M | $7.8M | $3.7M | $13.9M | $17.3M | $28.3M | $33.0M |
Cuenta de Resultados (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Ingresos | 0 | 0 | 0 | 0 |
| Beneficio Bruto | 0 | 0 | 0 | 0 |
| Beneficio Operativo | -$7.7M | -$10.9M | -$10.8M | -$12.5M |
| EBITDA | -$7.5M | -$10.6M | -$10.7M | -$11.5M |
| Beneficio Neto | -$7.6M | -$10.7M | -$10.1M | -$11.6M |
| BPA | $-0.24 | $-0.28 | $-0.18 | $-0.18 |
| BPA Diluido | $-0.24 | $-0.28 | $-0.18 | $-0.18 |
Balance (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Caja y Equivalentes | $734014 | $391086 | $17.6M | $13.4M | $17.5M | $17.7M | $93.9M |
| Inversiones a Corto | 0 | 0 | 0 | 0 | 0 | 0 | $6.5M |
| Cuentas por Cobrar | $175748 | $127436 | $25722 | $255705 | $1.2M | $2.0M | 0 |
| Inventario | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Corrientes | $933262 | $532236 | $18.2M | $14.9M | $19.8M | $20.2M | $101.2M |
| Inmovilizado Material | $9682 | $7361 | $5695 | $3560 | $50181 | $2.7M | $3.5M |
| Fondo de Comercio | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Intangibles | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Totales | $942944 | $539597 | $18.2M | $14.9M | $19.9M | $22.9M | $104.8M |
| Cuentas por Pagar | $247542 | $252344 | $142940 | $143074 | $1.4M | $5.4M | $5.4M |
| Deuda a Corto | $4.1M | $4.1M | $50000 | 0 | 0 | 0 | 0 |
| Pasivos Corrientes | $4.6M | $5.3M | $202039 | $1.3M | $3.7M | $8.7M | $10.1M |
| Deuda a Largo | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pasivos Totales | $4.6M | $5.3M | $202039 | $1.7M | $3.7M | $9.7M | $11.0M |
| Reservas | -$4.2M | -$5.4M | -$29.8M | -$38.0M | -$53.4M | -$75.0M | -$104.5M |
| Patrimonio Neto | -$3.6M | -$4.7M | $18.0M | $13.2M | $16.4M | $13.3M | $93.8M |
| Deuda Total | $4.1M | $4.1M | $50000 | 0 | 0 | $1.1M | $1.1M |
| Deuda Neta | $3.4M | $3.7M | -$17.6M | -$13.4M | -$17.5M | -$16.6M | -$99.3M |
| Capital Circulante | -$3.7M | -$4.7M | $18.0M | $13.6M | $16.1M | $11.5M | $91.1M |
Balance (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Caja y Equivalentes | $15.9M | $93.9M | $79.3M | $225.5M |
| Activos Totales | $20.1M | $104.8M | $95.8M | $239.1M |
| Pasivos Totales | $11.8M | $11.0M | $11.5M | $10.2M |
| Patrimonio Neto | $8.3M | $93.8M | $84.4M | $228.9M |
| Deuda Total | $1.1M | $1.1M | $1.0M | $1.0M |
Flujo de Caja (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Beneficio Neto | -$972811 | -$1.1M | -$24.4M | -$8.2M | -$15.6M | -$21.7M | -$29.4M |
| Amortizaciones | $1082 | $2321 | $2468 | $2135 | $5468 | $115388 | $364501 |
| Compensación en Acciones | 0 | 0 | $218983 | $624069 | $2.6M | $3.0M | $2.4M |
| Cambio en Capital Circulante | $181697 | $165848 | -$391035 | $195206 | $1.7M | $4.0M | $2.7M |
| Flujo de Caja Operativo | -$790032 | -$404694 | -$1.6M | -$7.4M | -$11.4M | -$14.6M | -$23.9M |
| Inversiones (CapEx) | -$7308 | 0 | -$802 | $3 | -$52089 | -$1.2M | -$732925 |
| Adquisiciones | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Recompra de Acciones | 0 | 0 | 0 | -$99963 | 0 | 0 | 0 |
| Dividendos Pagados | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Flujo de Caja Libre | -$797340 | -$404694 | -$1.6M | -$7.4M | -$11.4M | -$15.8M | -$24.7M |
Flujo de Caja (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Flujo de Caja Operativo | -$5.9M | -$11.0M | -$9.8M | -$11.7M |
| Inversiones (CapEx) | -$372456 | -$165126 | -$32486 | -$21043 |
| Flujo de Caja Libre | -$6.3M | -$11.2M | -$9.9M | -$11.8M |
| Dividendos Pagados | 0 | 0 | 0 | 0 |
| Compensación en Acciones | 0 | $570796 | $575565 | $978140 |
Crecimiento y Márgenes (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Crecimiento Beneficio Neto (anual) | | -18.0% | -2024.3% | +66.2% | -87.4% | -40.1% | -36.2% |
| Crecimiento BPA (anual) | | +48.3% | -4326.7% | +91.1% | -50.8% | +14.6% | -17.1% |
| Cambio en Acciones (anual) | | +130.3% | -52.8% | +278.1% | +24.9% | +63.1% | +16.5% |
| Crecimiento FCF (anual) | | +49.2% | -292.9% | -365.9% | -54.2% | -38.1% | -56.4% |
| Tasa Impositiva Efectiva | -2.2% | -1.6% | -0.0% | -0.1% | -0.2% | -0.2% | -0.1% |
Datos por Acción (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| FCF por Acción | $-0.24 | $-0.05 | $-0.43 | $-0.53 | $-0.66 | $-0.56 | $-0.75 |
| Dividendo por Acción | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Acciones en Circulación (Básicas) | $3.4M | $7.8M | $3.7M | $13.9M | $17.3M | $28.3M | $33.0M |
Qué mirar en Biotech
La mayoría de biotechs pequeñas pierden dinero. Analizarlas con P/E no tiene sentido — mira caja y pipeline.
- Cash Runway — Meses de caja al ritmo de gasto actual. <18 meses = riesgo de dilución urgente
- Cash burn anual — Ritmo al que queman caja operativa. Comparar con posición de caja para proyectar runway
- Total Debt — Biotech sin ingresos + deuda = receta para bancarrota
- I+D / Capitalización — Cuánto invierten en pipeline vs lo que vale la empresa — indicador de intensidad investigadora
- Market cap / Cash — Si cotiza cerca de su caja, el mercado le da ~0 valor al pipeline — puede ser oportunidad o trampa
Rentabilidad
| Rentabilidad sobre capital | -38.44% |
| Rentabilidad sobre capital invertido | -18.19% |
| Rentabilidad sobre activos | -16.69% |
| Margen bruto | 0.00% |
| Margen operativo | 0.00% |
| Margen neto | 0.00% |
Salud financiera
| Deuda / Patrimonio | 0.00 |
| Ratio corriente | 25.13 |
Ratios Clave (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| P/E | -12.66 | -24.47 | -0.54 | -3.88 | -7.78 | -2.89 | -5.88 |
| P/VC | -3.40 | -6.03 | 0.73 | 2.42 | 7.31 | 4.70 | 1.84 |
| P/V | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Margen Bruto | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Margen Operativo | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Margen Neto | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |